This paper presents the results of clinical studies on cefuroxime in the treatment of infections in the urological, surgical and gynecological fields. Since the studies have been started recently and cases have been collected from many institutes, the results of long-term follow-up studies are not yet available. Therefore, the data presented here are the results of preliminary studies showing the immediate response to the medication.
Clinical Studies in Cefuroxime in the Urological and Surgical Fields by Professor Y Naide and Dr K Niimura (Fujita-Gakuen University School ofMedicinte, Toyoake-shi, Japan) This paper presents the results of clinical studies on cefuroxime in the treatment of infections in the urological, surgical and gynecological fields. Since the studies have been started recently and cases have been collected from many institutes, the results of long-term follow-up studies are not yet available. Therefore, the data presented here are the results of preliminary studies showing the immediate response to the medication.
Patients and Methods
The reported cases are mostly urinary tract infections and only a few assessable cases have been obtained so far in the surgical and gynacological fields. Most of the patients were inpatients, except 4 cases of acute gopococcal urethritis. Simple acute cystitis was excluded from our statistics since these cases seemed rather inappropriate to be treated with drugs given only by the parenteral route. A total of 73 patients with genitourinary infections and 3 cases each of surgical and gynecological infections were treated with cefuroxime. Acute bacterial prostatitis and gonococcal urethritis were the genital infections involved in this study.
As shown in Table 1 , the genitourinary infections were classified into 4 groups. In both upper and lower urinary tract infection the groups were further divided into sub-groups of acute symptomatic cases, acute exacerbation of chronic infections and asymptomatic infections.
About two-thirds of the male patients were in their sixth decade or older. The females showed a rather more even age distribution.
Identification of the bacteria was carried out in the laboratory of each hospital. Sensitivity testing of the pathogens was mostly by disc diffusion method. Hxmatology and blood chemistry were routinely carried out. The dosage regime varied but a twice daily regimen was preferred to a three times daily administration in most hospitals. Criteria for efficacy are as follows. Good in cases where eradication of bacteria was seen in association with prompt remission of symptoms in symptomatic cases. Poor in cases when no bacteriological response was seen, or no remission of fever was seen in febrile patients. Superinfection for the cases in whom a change of bacterial flora was seen. In asymptomatic cases, bacteriological response was the only indicator adopted.
Results
The results of treatment with cefuroxime are summarized in Table 2 . In 30 upper urinary tract infections only 2 cases were reported as poor, and 4 superinfections were seen. In contrast, in lower urinary tract infections, a much higher percentage of poor response is seen, especially in asymptomatic cases. An indwelling catheter was left in place in only 3 good cases and I of suiperinfection.
In poor cases, Escherichia coli strains were very sensitive to cefuroxime, but predisposing factors were believed to play a role in the establishment of infection. In the first case, the patient had undergone surgery for hydronephrosis prior to the infection and the second patient had been suffering from hypertensive heart failure. In acute bacterial prostatitis and gonococcal urethritis, response was satisfactory in all 6 cases. In gonococcal urethritis, a single injection of 1500 mg of cefuroxime was effective and no relapse was seen over a one-week follow-up.
In one instance of peritonitis and 2 soft tissue infections, response was satisfactory in every case. eliminated. It should be emphasized that an Escherichia coli strain replaced the Klebsiella. Such cephalosporin resistant Escherichia coli have been isolated with increasing frequency in Japan and might be expected to increase further in the near future.
Cefuroxime was effective on all 6 cases of indole positive Proteus strains, another fact which should be emphasized. In 4 cases of gonorrhoea, complete cure was reported with I x 1500 mg dose of cefuroxime. In a Serratia infection, a moderate decrease in viable cell numbers was noticed, but it was not so marked as to be diagnosed as effective. In a Citrobacter infection, cefuroxime was also ineffective but in 2 Streptococcal infec-7 tions (I facalis and I viridans) bacteriuria was cleared.
In 17 other cases, mixed infections were found (Table 4 ). In most of these, Gram negative rod strains were included. In 12 patients the organisms were eradicated completely but in 4 cases one organism was selectively eradicated. There were 1 2 superinfections of Streptococcusfcalis.
Twice daily administration was preferred in L most hospitals. Therefore, the relationship between the daily dose schedules and efficacy was not estimated from these data, presented inTable 5. (1), unidentified Gram negative rod (1); b = Citrobacter (1), Serratia (1); I =Streptococcusfecalis (1), Streptococcus viridans (1) Two puerperal infections and one salpingitis were cured. The data are summarized in Tables 3 and 5  and Table 3 also shows bacteriological data in cases infected by a single pathogen. Of 61 organisms, 31 were Escherichia coli; 24 of them were eliminated and 2 were persistent after cefuroxime treatment. In 5 cases Escherichia coli was The observed untoward reactions are listed in Table 6 . Skin rashes were seen in 3 cases. In one, after 5 days of administration a rash developed on whole body surface and the drug was discontinued. In the second, a general skin rash developed after 2 i.m. injections and the therapy was discontinued. In the third, a general skin rash developed on the third medication day. The medication was discontinued and the rash was cured in 5 days after cessation of the drug. An eosinophilia was noticed (10 %) after 3 weeks of medication with cefuroxime. Transient nausea and vomiting was noticed in 1 case. In 2 cases transient numbness was noticed during the course of treatment but medication was continued with great care, and no recurrence of this symptom was complained of. In 41 patients given i.m. injections, 17 (41.5%) complained of severe pain at the injection site in more extended studies.
Discttssion and Conclusions
Throughout this clinical therapeutic trial with cefuroxime, it has been shown that cefuroxime is satisfactorily effective in the treatment of genitourinary infections, especially those caused by Klebsiella, Enterobacter and Proteus, unless host factors play a prominent role in the establishment ofthe infections. Although Pseudomonas aruginosa infections are not good indications for this drug, Pseutdomonas cepacia and Psettdomonas pittrefaciens were shown to be sensitive to it during in vitro studies and cefuroxime was clinically effective against 1 Pseudomonas infection (its species was unidentified).
As to Serratia infection, though many clinical isolates belonging to this species were resistant to the drug, some strains were shown sensitive to cefuroxime and the effectiveness of the drug in clinical trials was also shown in a few cases. Evaluation of cefuroxime in Serratia infection might be a subject for future investigation.
Most of the trials in Japan have been done on a twice daily dosage regimen, as opposed to the three times daily regimen recommended from the basic pharmacodynamic data. However, the effectiveness of cefuroxime has been clearly seen, even on twice daily regimen. This question should be further studied in future trials.
As to untoward reactions, the drug seems adequately safe for widespread use in many infections, because of the reasonably low rate of observed allergic reactions. Transient nausea and vomiting, and numbness, might be due to the speed of injection, since they were seen only in cases of bolus administration.
Professor Brumfitt (Chairman) asked Dr Boewering what was the concentration of cefuroxime in the discs he used for MIC determinations. Also he wondered what sort of clinic had been involved since there was a scattered population of organisms which would not have been seen in general practice.
Dr Boewering said the concentration was 30 ,ug in the disc.
He had been working in a department of urology with problem patients who had a different spectrum of pathogens from those seen in general urological practice.
Professor Brumfitt (Chairman) said that the studies had been carefully performed but were not controlled against another antibiotic. Therefore if the same organism persisted the case was a failure, but having eradicated the organism, even if there was a new infection, the case should be regarded as a success.
Professor Naide agreed.
Professor Gomez-Lus also agreed. It was, however, very important to serotype the microorganisms in order to establish whether the original pathogen had been removed. Dr J D Price (Londoni) said that in most of the analyses of data so far undertaken, patients who at the end of therapy had an organism in the urine found to be sensitive to the test drug were regarded as bacteriological failures. If the elimination of the original organism were regarded as a success (even though another organism may be present at the end of therapy) this would produce a very different set of results to the total so far presented by various clinicians in trials around the world.
Professor Brumfitt (Chairman) said that the Medical Research Council was going to report on this subject in an attempt to distinguish relapse from reinfection. It was difficult in the case of relapse, because one did not know whether the organism had survived on the perineum and then reinfected. But the distinction was far simpler in a change from, say, Proteuts to Escherichia coli.
Dr J R T Gabriel (Londonz) said that cefuroxime was obviously a valuable antibiotic. Perhaps it should not be used except in those cases where multiple drug resistance was present, either in urinary or in other infections.
Professor Brumfitt (Chairman) said that he was interested in Professor Gomez-Lus's serotype because the E. coli strains he described were not the ones commonly associated with urinary infection occurring outside hospital.
Professor Gomez-Lus said that they too had been surprised but they had verified the prevalence of the serotypes and found that there was no significant difference between the microorganism types isolated inside and outside the hospital.
They had also performed some specific antibody determinations in 14 cases of pyelonephritis. They had found titres at least as high as 1:640 in 12 of them.
Dr L D Sabath (Minneapolis) said that pyelonephritis was generally thought of as being due to a single organism, but if 2 were present and only I were initially diagnosed, this might explain the superinfection. He noticed that Professor Naide had a 13 % incidence of superinfection in patients with pyelonephritis and he asked whether a catheter had frequently been left in place.
Professor Naide said cases had been collected from many institutes and some of them could have been infected by more than one organism. A catheter had not been left in place in most cases and the organisms had probably been present before starting medication.
Dr J D Price (Londoni) asked Professor Naide for more details of the 17 out of 41 patients complaining of pain when injections were given i.m.
Professor Naide thought that pain on i.m. injection might be due to the relatively high volume (nearly 5 ml) of solvent. Some patients complained of pain after several injections and he therefore preferred the i.v. route.
Dr T Tupasi (Philippines) said that most authorities on urinary tract infection recommended treatment for at least 14 days and even longer in acute upper tract infections. Speakers had presented data on 5 and 10 day treatments. She wondered if there was enough information on relapse rate to show that such a duration of treatment was adequate.
Professor Brumfitt (Chairmani) said that his studies had shown no difference between I week, 2 weeks or 6 weeks for eradication of the organism, providing the dose was adequate and the patient took it.
Dr Boewering agreed. His mean treatment period had ranged from 8-15 days. If there was no clinical result, the treatment was stopped at 4 days.
Dr H H Schassen (Hamburg) said that Dr Boewering had shown a discrepancy between laboratory test results for enterococci and response to cefuroxime. He wondered whether susceptibility testing gave an indication of response to cefuroxime in enterococci infections. Dr Boewering said that it did. Of 8 cases of enterococci, 6 were sensitive and 2 were resistant and the clinical response corresponded to the bacteriological finding.
